Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 1, 2020
Daily News
September 1, 2020
- Japan Rolls Out Full-Fledged Sakigake System, Designations 2 Times a Year with Tougher Revocation Rules
September 1, 2020
- Fujifilm Files Radiopharmaceutical Drug F-1515 in Japan
September 1, 2020
- Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
September 1, 2020
- Sanofi’s Sarclisa Hits Japan Market, Zeria Launches Ferinject
September 1, 2020
- AMED to Focus on 5 Initiatives Including Strengthening Cooperation with Govt: New Chief
September 1, 2020
- Edoxaban Hits PIII Goal in Very Elderly Patients: Daiichi Sankyo
September 1, 2020
- Healthcare Spend Reaches Record 43.6 Trillion Yen in FY2019: MHLW
September 1, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…